Abstract-The vasodilatory capacity of insulin has been widely reported, yet some investigators have not noted this effect.
T he ability of insulin to induce vasodilation is integral to the regulation of skeletal muscle blood flow and glucose delivery. [1] [2] [3] Insulin-mediated vasodilation is impaired in insulin-resistant patients, suggesting a close relation between insulin resistance and hypertension. 4, 5 However, despite the potential significance, the mechanism(s) underlying direct vascular effects of insulin remain controversial. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Several studies in animals and humans attribute the vasodilatory effect of insulin to enhanced generation of endotheliumderived nitric oxide (EDNO). 2, [11] [12] [13] [14] [15] [16] On the contrary, there have been reports supporting an endothelium-independent mechanism. [5] [6] [7] [8] [9] [10] Incubation with insulin has been shown to reduce cytosolic-free calcium levels 6 and to increase the expression of the sodium pump gene, leading to hyperpolarization of vascular smooth muscle (VSM) cells. 7 Insulin enhancement of vascular ␤-adrenergic responsiveness has also been reported in normotensive animals and humans. 8, 9 In the perfused rat mesenteric vascular bed (MVB), insulinevoked vasodilation has been linked to the activation of calcitonin gene-related peptide receptors on the VSM cells. 10 Interestingly, these investigators noted that endothelial denudation of the MVB enhanced vasodilator responses to insulin, implicating the release of a contracting factor from the endothelium. 10 Moreover, a few reports have demonstrated the lack of a vasodilator response to insulin. 17, 18 Therefore, an explanation that insulin is simultaneously promoting the release of a contractile substance countering the release of vasodilator factor(s) is indeed possible, because several in vitro and in vivo studies have shown that insulin promotes endothelin-1 (ET-1) generation in the vascular endothelium. 19 -24 This activity may account for the paradoxical vascular effects of insulin. To assess this hypothesis, we investigated the endothelium-dependent and endotheliumindependent effects of insulin on the vasculature. The perfused rat MVB was used because it is a well-established representation of vascular resistance function. 25 
Methods

MVB Perfusion
Experiments were performed with 80 male Sprague-Dawley rats (Charles River) weighing 410 to 515 g. Animals were killed under pentobarbital anesthesia (65 mg/kg IP). All procedures were conducted in accordance with the guidelines of the university animal care committee. The vascular bed was removed, cannulated, and perfused as previously described. 26 An equilibration period of 30 minutes was allowed to stabilize the baseline. This was followed by perfusion of a Krebs solution containing the ␣ 1 -agonist methoxamine (MTX, 70 mol/L), either in the presence or absence of the following agents: (1) a combination of nitric oxide synthase (NOS) inhibitors N-nitro-L-arginine (L-NNA, 100 mol/L) and N G -nitro-L-arginine-methylester (L-NAME, 100 mol/L) to maximally inhibit the enzyme; (2) a calcium-activated potassium channel blocker (K Ca ), which serves as an endothelium-derived hyperpolarizing factor [EDHF] blocker, (tetrabutylammonium [TBA], 0.5 mmol/L); (3) a cyclooxygenase inhibitor (indomethacin, 10 mol/L); (4) an ET A receptor blocker (BQ123,100 nmol/L); (5) an ET B receptor blocker (BQ788, 100 nmol/L); and (6) a combination of ET A and ET B receptor blockers (BQ123 and BQ788, 100 nmol/L each). Denudation was accomplished as previously described. 26 The MTXinduced elevation in baseline PP was allowed to stabilize for 20 to 30 minutes before the remainder of the protocol was conducted. After 20 to 30 minutes, a maximal dose of acetylcholine (ACh) was injected into the perfusate. A washout was then allowed before insulin perfusion was initiated. On stabilization of the MTXconstricted baseline, insulin was added to the perfusate in concentrations of 3.0 pmol/L, 10 pmol/L, 30 pmol/L, 100 pmol/L, 300 pmol/Lѧ3.0 mol/L sequentially, and each concentration was perfused for 4 minutes, resulting in a cumulative response. Single concentrations of insulin (1.0 nmol/L or 10 nmol/L) and insulinderived growth factor (IGF)-1 (1.0 nmol/L and 10 nmol/L) or MTX alone was also included in the perfusate over a period of 1 hour (nϭ4). To assess the postinsulin vasodilation capacity of the VSM, a maximal dose of a direct NO donor, sodium nitroprusside (SNP), was injected.
Assessment of Endothelin Generation
To assess whether the loss of insulin-induced vasodilation was attributable to ET, we collected the MVB perfusate for 10 minutes during both the baseline and MTX equilibration periods. After this, perfusate was collected every 10 minutes for 1 hour during exposure to fixed concentrations of insulin, IGF-1, or MTX as a control. The ET level in the perfusate was measured with a sensitive enzymelinked immunosorbent assay kit as previously described. 27 Reagents MTX, TBA, L-NNA, L-NAME, indomethacin, ACh, SNP, and insulin (human USP) were all purchased from Sigma. Alcohol was used to dissolve indomethacin at a final concentration of 1/2000 and was added to all solutions. BQ123 and BQ788 were obtained from American Peptide. Krebs solution salts were obtained from BDH. The enzyme-linked immunosorbent assay kit was obtained from Biomedica Gruppe. Amprep Octadecyl C18 columns were from Amersham.
Statistical Analysis
Cumulative concentration-response curves were analyzed individually. The results are expressed as the percentage of vasodilation of MTX-evoked contraction. The potency of insulin-induced vasodilation was expressed as the negative logarithm of the half-maximal response (pD 2 value). Both maximal responses and the pD 2 were expressed as meanϮSEM. Comparison of mean values among various groups was performed by ANOVA methodology (Superanova program-SAS Institute). Simultaneous multiple comparisons were examined by Scheffé's F test.
Results
Vascular Responses to Perfusion of Insulin
Perfusion of the MVB with MTX resulted in a vasoconstriction and an elevation in the PP (49.0Ϯ5.1 mm Hg). In MTX-preconstricted preparations, cumulative insulin perfusion resulted in a concentration-dependent decrease in PP. At concentrations of insulin Ͼ10 nmol/L, the decrease in PP gradually diminished such that at a maximal concentration of insulin (3 mol/L), there was no decrease in PP. A representative tracing from a single experiment is shown in Figure 1 . The pD 2 value for the insulin-mediated vasodilation was 10.3Ϯ0.1 (Ϫlog mol/L), and the maximal relaxation of MTX-induced PP was 42.0Ϯ9.2% (Table) . The continuous perfusion of a fixed concentration of insulin (1.0 nmol/L) induced vasodilation (31.0Ϯ2.2%) shortly after being exposed to the MVB, whereas perfusion of insulin (10 nmol/L) produced a larger relaxation of 51.8Ϯ3.5% (PϽ0.01). By comparison, the maximal relaxation response attained with ACh and SNP as vasodilatory agents were 93.0Ϯ7.8% and 98.4Ϯ4.4%, respectively. The basal ET level in the perfusate was 46.5Ϯ7.2 pg/50 mL. There was no significant change in ET levels when MTX alone was perfused for a period of 1 hour (Figure 2A ). Although continuous perfusion of a fixed concentration of insulin (1 nmol/L) did not evoke an increase in ET production after 1 hour (data not shown), insulin (10 nmol/L) significantly increased (PϽ0.01) ET generation at a 20-minute time period and thereafter ( Figure 2A ). This was accompanied by a gradual loss of the vasodilatory response, as depicted in the representative tracing of a single experiment (see Figure 2B) . The residual vasodilation after perfusion of 10 nmol/L insulin for 1 hour was 5.6Ϯ3.2%. Perfusion of IGF-1 for up to 1 hour did not affect the changes in PP to MTX (data not shown).
Effects of Treatment on Insulin Perfusion
Inclusion of inhibitors of endothelium-mediated vasodilation and contraction in the perfusion solution did not have any significant effect on the MTX-induced increase in PP. Endothelial denudation (PϽ0.01), NOS inhibition (PϽ0.05), and TBA (PϽ0.05) reduced the maximal vasodilator responses to ACh, whereas neither indomethacin nor ET antagonists had any effect. Endothelial denudation significantly attenuated (PϽ0.01) insulin-induced vasodilation ( Figure 3A) , resulting in both a decrease in the maximal vasodilation (PϽ0.01) and a right shift in the concentration-response curve (PϽ0.01; Table) . NOS inhibition (PϽ0.01) and TBA (PϽ0.05; Figure  3B ) both attenuated insulin-evoked maximal dilation (Table) . ET A and nonselective ET-receptor blockade prevented the loss of vasodilation associated with insulin concentrations starting at 10 nmol/L ( Figure 3C ). Neither selective ETreceptor blockade nor nonselective ET blockade produced any significant change in the potency or maximal effect of insulin-evoked vasodilation (Table) . Maximal SNP responses did not differ among the groups. 
Effects of Treatment on pD 2 and Percent Maximal Vasodilation of MTX-Induced (70 mol/L) Tone Produced by Insulin in Perfused MVB of Sprague-Dawley Rats
Discussion
The results of this investigation demonstrate a concentrationdependent effect of insulin on vascular reactivity and that in the presence of higher concentrations, the duration of exposure is of consequence. The ability of NOS inhibition and K Ca blockade to attenuate the initial vasodilatory response suggests the involvement of EDNO and EDHF. Although at higher concentrations, insulin initially produces a more profound vasodilation than at lower doses, sustained exposure stimulates the production and release of ET, which diminishes the preceding vasodilation. Subsequently, ET-receptor blockade maintains vasodilation. Because the MVB contributes significantly to the resistance function of the vasculature, 25 the present study supports the notion that hyperinsulinemic-evoked imbalances in endothelium-derived factors may contribute to insulin-resistant hypertension. A recent investigation by Cardillo et al 16 also demonstrated the ability of ET-receptor blockade to increase forearm blood flow during hyperinsulinemia. Insulin has been shown to have profound effects on the ET system, promoting the release of ET-1 19 -24 and upregulating ET receptors on VSM cells. 28, 29 Incubation of bovine aortic endothelial cells with insulin in vitro increases the production and release of ET-1 within 10 minutes, an effect that was maximal within 1 to 2 hours. 19 -20 Our results are consistent with these in vitro observations. Insulin also increases ET-1 production in cultured human VSM cells, 21 supporting the finding of enhanced ET release in both healthy as well as obese non-insulin-dependent diabetes mellitus human subjects. 22, 23 The concentration of insulin (10 nmol/L) that evoked significant ET generation in the present study may be relevant to in vivo situations because similar concentrations of plasma insulin have been detected in hyperinsulinemic Zucker obese rats. 30 Furthermore, an in vitro study with femoral artery isolated from Wistar rats used a much higher concentration of insulin (300 nmol/L) to demonstrate a significant increase in KCl-induced vascular contractility. This effect of insulin was attenuated by inclusion of either an ET antagonist or ET antiserum. 24 ET has an autocrine influence on endothelial-cell ET B receptors, promoting a transient vasodilation through the release of NO. 31 However, ET B -selective antagonism failed to attenuate insulin-induced dilation. Because insulin-evoked NO generation has been shown to be dependent on tyrosine kinase/phosphatidylinositol 3-kinase, 12, 13 it is possible that although present, the transient ET B -receptor-mediated NO release made a minimal contribution. It is also possible that ET is not being generated in substantial quantities in this vascular bed during the early vasodilatory phase of the response. The inability of ET B receptor blockade to produce a significant shift in the vasodilatory pD 2 confirms that NO (and EDHF) activity is functionally independent of the ET B receptor. Although the functional importance of ET B receptors on VSM is thought to be minimal, the characterization of ET B receptors on the rat mesenteric VSM cells helps to explain the ability of BQ788 to attenuate ET B -mediated vasoconstriction. 32 Although the existence of a non-EDNO entity that induces vasodilation through TBA-sensitive potassium conductance has been established, 33 this is the first report of two endothelium-derived autocoids mediating an insulin-evoked vasodilation. Little is conclusive about EDHF except that it produces vasodilation during NOS inhibition and that its release is probably linked to an increase in intracellular calcium. The vasodilator effect of insulin could not be attributed to its direct effects on VSM cells because no decrease in response to SNP after insulin infusion was noted. Because endothelial denudation prevented an increase in vascular tone, the involvement of an endothelium-derived vasoconstrictor is probable. Because indomethacin did not significantly alter the dynamics of the response, it is unlikely that a cyclooxygenase-dependent factor was responsible. However, because exogenous insulin may augment cardiovascular reactivity to norepinephrine (NE), 34 it is possible that the loss of vasodilation was due to the effects of insulin on MTX-induced vasoconstriction. A recent study has indeed demonstrated that incubation with a high dose (715 nmol/L) but not a low dose (715 pmol/L) of insulin increases the vasoconstrictor effect of NE in resistance vessels of spontaneously hypertensive rats. 35 This effect was attenuated by ET-receptor blockade, suggesting that enhanced NE responses were at least partially mediated by ET. Accordingly, ET-1 has been reported to enhance adrenergic vasoconstriction, 36 suggesting that sympathetic activation in hyperinsulinemic states could be linked to ET. 9 This study demonstrates the importance of the endothelium in regulating the vascular effects of insulin. Interestingly, ET-receptor blockade maintains insulin-mediated vasodilation in the presence of hyperinsulinemia, suggesting a role for these agents in hyperinsulinemic hypertension. We have also demonstrated the involvement of both EDNO and EDHF; however, the recruitment of autacoids is dependent on the type of vascular tissue 37 as well as on vascular pathology. 38 Furthermore, comorbid factors such as hypertriglyceridemia and hypercholesterolemia 19 -23,39 may contribute to increased ET generation, 23, 39, 40 which in turn could affect EDNO and/or EDHF. 39 Because of this complexity of interaction between endothelial factors, more detailed studies of ET blockers in various vascular beds of insulin-resistant models are required.
